针对2型细胞因子的生物疗法在改善喘症状和控制方面是有效的 - - 一项系统性审查和元分析
Rebecca E Bignold1, Hannah Busby1, Jenny Holloway1
1School of Biosciences, College of Health and Life Sciences, Aston University, Birmingham, United Kingdom.
The journal of allergy and clinical immunology. Global
|January 23, 2025
概括
针对TH2细胞因子的生物疗法,包括IL-5和IL-4/IL-13抑制剂,显著改善了喘控制. 这些先进的治疗方法可以增强肺功能,减少恶化,为严重过敏喘患者提供新的希望.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
背景情况:
- 过敏性喘是一种广泛的慢性炎症状况,由环境过敏原引发.
- 目前治疗严重喘的方法往往无法完全控制症状,这凸显了大量未满足的医疗需求.
- 针对IL-4,IL-5和IL-13等关键细胞因子的生物疗法在改善患者的治疗结果方面表现有前途.
研究的目的:
- 进行一项元分析,评估生物疗法在治疗喘方面的疗效.
- 评估IL-5和IL-4/IL-13抑制剂对肺功能,症状控制和喘患者皮质类固醇使用的影响.
主要方法:
- 对14项临床试验 (2013-2020年) 的数据进行了元分析,涉及6600名严重喘患者 (年龄大于12岁) 的参与者.
- 通过对PubMed,科学网,Scopus和clinicaltrials.gov.gov的全面搜索来确定试验.
- 该研究批判性地评估了IL-5和IL-4/IL-13生物抑制剂与安慰剂相比的影响.
主要成果:
- IL-5抑制剂在FEV1,喘控制问卷得分,每年恶化率降低和口服皮质类固醇使用量的显著改善.
- 抗IL-4/IL-13疗法在FEV1,喘症状控制和恶化减少方面也显示出显著的益处.
- 然而,与安慰剂相比,抗IL-4/IL-13抑制剂与较高的不良事件发生率有关.
结论:
- 针对TH2细胞因子的生物抑制剂为增强整体喘控制提供了相当大的好处.
- 这些向疗法在治疗严重过敏性喘方面取得了重大进展.
- 进一步的研究可能是有必要的,以充分了解抗IL-4/IL-13药物的风险-益处概况.
相关概念视频
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
236
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
236
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
217
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
217
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
231
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
231
01:19Antiasthma Drugs: Leukotriene Modifiers
240
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
240
01:17Drugs Used in Lower Respiratory Disorders: Overview
349
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
349